Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

BACKGROUND: Sodium glucose cotransporter‐2 inhibitors reduce systolic blood pressure (SBP), but whether they affect SBP variability is unknown. There also remains uncertainty regarding the prognostic value of SBP variability for different clinical outcomes. METHODS AND RESULTS: Using individual part...

Descripción completa

Detalles Bibliográficos
Autores principales: Fletcher, Robert A., Arnott, Clare, Rockenschaub, Patrick, Schutte, Aletta E., Carpenter, Lewis, Vaduganathan, Muthiah, Agarwal, Rajiv, Bakris, George, Chang, Tara I., Heerspink, Hiddo J. L., Jardine, Meg J., Mahaffey, Kenneth W., Neal, Bruce, Pollock, Carol, Jun, Min, Rodgers, Anthony, Perkovic, Vlado, Neuen, Brendon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356084/
https://www.ncbi.nlm.nih.gov/pubmed/37345834
http://dx.doi.org/10.1161/JAHA.122.028516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356084/
https://www.ncbi.nlm.nih.gov/pubmed/37345834
http://dx.doi.org/10.1161/JAHA.122.028516

Ejemplares similares